Literature DB >> 23774812

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

Nancy J Brown1.   

Abstract

The steroid hormone aldosterone regulates sodium and potassium homeostasis. Aldosterone and activation of the mineralocorticoid receptor also causes inflammation and fibrosis of the heart, fibrosis and remodelling of blood vessels and tubulointerstitial fibrosis and glomerular injury in the kidney. Aldosterone and mineralocorticoid-receptor activation initiate an inflammatory response by increasing the generation of reactive oxygen species by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondria. High salt intake potentiates these effects, in part by activating the Rho family member Rac1, a regulatory subunit of reduced NADPH oxidase that activates the mineralocorticoid receptor. Studies in mice in which the mineralocorticoid receptor has been deleted from specific cell types suggest a key role for macrophages in promoting inflammation and fibrosis. Aldosterone can exert mineralocorticoid-receptor-independent effects via the angiotensin II receptor and via G-protein-coupled receptor 30. Mineralocorticoid-receptor antagonists are associated with decreased mortality in patients with heart disease and show promise in patients with kidney injury, but can elevate serum potassium concentration. Studies in rodents genetically deficient in aldosterone synthase or treated with a pharmacological aldosterone-synthase inhibitor are providing insight into the relative contribution of aldosterone compared with the contribution of mineralocorticoid-receptor activation in inflammation, fibrosis, and injury. Aldosterone-synthase inhibitors are under development in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774812      PMCID: PMC3922409          DOI: 10.1038/nrneph.2013.110

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  129 in total

Review 1.  Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ.

Authors:  Vivek Bhalla; Rama Soundararajan; Alan C Pao; Hongyan Li; David Pearce
Journal:  Am J Physiol Renal Physiol       Date:  2006-05-23

2.  Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

Authors:  Shigeru Shibata; Miki Nagase; Shigetaka Yoshida; Hiroshi Kawachi; Toshiro Fujita
Journal:  Hypertension       Date:  2007-01-02       Impact factor: 10.190

3.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

4.  Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.

Authors:  Yuki Hirono; Takanobu Yoshimoto; Noriko Suzuki; Toru Sugiyama; Maya Sakurada; Shinji Takai; Naohiko Kobayashi; Masayoshi Shichiri; Yukio Hirata
Journal:  Endocrinology       Date:  2007-01-11       Impact factor: 4.736

5.  Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1.

Authors:  Ferruh Artunc; Kerstin Amann; Omaima Nasir; Björn Friedrich; Diana Sandulache; Nermina Jahovic; Teut Risler; Volker Vallon; Peer Wulff; Dietmar Kuhl; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-08-10       Impact factor: 4.599

6.  Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter.

Authors:  Claudia Grossmann; Alexander W Krug; Ruth Freudinger; Sigrid Mildenberger; Katharina Voelker; Michael Gekle
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-02-20       Impact factor: 4.310

7.  Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype.

Authors:  Ivan C Gerling; Yao Sun; Robert A Ahokas; Linus A Wodi; Syamal K Bhattacharya; Kenneth J Warrington; Arnold E Postlethwaite; Karl T Weber
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-08       Impact factor: 4.733

8.  Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.

Authors:  Sameer Stas; Adam Whaley-Connell; Javad Habibi; Lama Appesh; Melvin R Hayden; Poorna R Karuparthi; Mahnaz Qazi; E Matthew Morris; Shawna A Cooper; C Daniel Link; Craig Stump; Meredith Hay; Carlos Ferrario; James R Sowers
Journal:  Endocrinology       Date:  2007-05-10       Impact factor: 4.736

9.  Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin.

Authors:  Aihua Zhang; Zhanjun Jia; Xiaohua Guo; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2007-06-27

10.  Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells.

Authors:  Jun Yuan; Ruhan Jia; Yan Bao
Journal:  J Biochem Mol Biol       Date:  2007-03-31
View more
  116 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

3.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

Review 4.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

Review 5.  Overnutrition, mTOR signaling, and cardiovascular diseases.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-24       Impact factor: 3.619

6.  Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats.

Authors:  Javad Habibi; Melvin R Hayden; Carlos M Ferrario; James R Sowers; Adam T Whaley-Connell
Journal:  Cardiorenal Med       Date:  2014-03-14       Impact factor: 2.041

Review 7.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

8.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

Review 9.  Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.

Authors:  RenJie Lu; Yan Zhang; Xishan Zhu; Zhengda Fan; Shanmei Zhu; Manman Cui; Yanping Zhang; Fenglei Tang
Journal:  Int Urol Nephrol       Date:  2016-05-18       Impact factor: 2.370

Review 10.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.